- Recombinant vectors deliver gene fragments used in vaccines to boost the immune system
- Bluebird in September submitted to FDA its application for beti-cel, made using BB305 lentiviral vector, and it’s marketing beti-cel as LentiGlobin for treating sickle cell disease and as Zynteglo for beta thalassemia, according to a
complaintfiled Thursday in federal court in Wilmington, Delaware
- Errant is seeking at least a reasonable royalty and either court order blocking ...
Oct. 21, 2021, 9:56 PM
Bluebird Is Sued Over Patents Related to Blood-Disease Drug